Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMHR2-ED vaccine
- Development stage
- Preclinical
- Lead developer
- Anixa Biosciences
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
01
Overview
Anixa Biosciences' ovarian cancer vaccine is an investigational nucleic acid-based immunotherapy designed to prevent and treat ovarian cancer by targeting the extracellular domain of the anti-Mullerian hormone receptor II (AMHR2-ED). Developed in collaboration with the Cleveland Clinic and the National Cancer Institute, the vaccine utilizes the "retired protein" concept, targeting a protein that is expressed in the ovaries during certain life stages but is overexpressed in ovarian cancer cells. By encoding the AMHR2-ED polypeptide, the vaccine aims to stimulate the immune system to recognize and eliminate emerging malignant cells, particularly in high-risk individuals such as those with BRCA1/2 mutations or a strong family history of the disease.
- Other names
- anti-Mullerian hormone receptor II extracellular domain vaccineAnixa ovarian cancer vaccineAnixa Biosciences-AMHR2-ED-anti-Mullerian hormone receptor II (extracellular domain)-vaccine-ovarian cancer
02
Targets
AMHR2 (Anti-Müllerian hormone receptor type 2)
Beyond the preview
Go deeper on AMHR2-ED vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMHR2-ED vaccine.